Pharmacoepidemiological research using French reimbursement databases: Yes we can!

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 3, 2010, Pages 256-265

  Martin Latry, Karin ^a,b   Bégaud, Bernard ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Databases; Factual; France; Health; Insurance; Pharmaceutical preparations; Pharmacoepidemiology; Reimbursement

Indexed keywords

ADULT; ARTICLE; CASE REPORT; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG RESEARCH; DRUG USE; DRUG UTILIZATION; FRANCE; HEALTH CARE FINANCING; HEALTH INSURANCE; HEALTH SERVICE; HOSPITAL COST; HUMAN; INFORMATION RETRIEVAL; MEDLINE; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PRIVATE HOSPITAL; PUBLIC HOSPITAL; PUBLICATION; REIMBURSEMENT;

EID: 77649224129     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1912     Document Type: Article

References (125)

1. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323-337. DOI S0895-4356(04)00298-7 [pii]. 10.1016/j.jclinepi. 2004.10.012. eng
2. Strom B. Pharmacoepidemiology, JWaS Ltd. (ed.). Chichester: 2006; 446p.
3. http://www.ecosante.fr. [Accessed 18 February 2009].
4. http://www.ameli.fr. [Accessed 15 February 2009].
5. http://www.cmu.fr. [Accessed 15 February 2009].
6. [Article L.161-31 du Code de la Sécurité Sociale. Modifié par Loi no2004-1370 du 20 décembre 2004 - art. 35 JORF 21 décembre 2004]. http://www.legifrance.gouv.fr/affichCodeArticle. do;jsessionid=3979474F2F39BD5C59232C1F5DEFB0BC.tpdjo07v-2?idArticle= LEGIARTI000006740721&cidTexte=LEGITEXT000006073189&dateTexte= 20090314 [Accessed 25 July 2009].
7. http://www.le-rsi.fr. [Accessed 18 February 2009].
8. http://www.msa.fr. [Accessed 18 February 2009].
9. Décision relative à la mise à disposition des Caisses Primaires d'Assurance Maladie d'un système d'analyse de fichiers (SIAM). http://www.mediam.ext.cnamts.fr/cgi-ameli/aurweb/ACIRCC/LISTE? OBJ=siam&TYPRECH=MULTI [Accessed 25 February 2009].
10. Décision modificative Hippocrate. http://www.ameli.fr/fileadmin/ user-upload/documents/cnil-120706-hypocrate.pdf [Accessed 20 February 2009].
11. Codage pharmacie. Acte réglementaire publié au bulletin juridique de l'UCANSS No39-1996 du 5 novembre 1996. http://www.mediam. ext.cnamts.fr/ameli/cons/CIRCC/CC9709/970922-C.PDF [Accessed 25 February 2009].
12. Fender P, Weill A. Epidemiology, public health and medical rates databases. Rev Epidemiol Sante Publique 2004; 52: 113-117. French.
13. Ricordeau P, Weill A, Vallier N, et al. Epidemiology of diabetes in metropolitan France. Diabetes Metab 2000; 26 (Suppl 6): 11-24. French.
14. Latry P, Pinet M, Labat A, et al. Adherence to anti-inflammatory treatment for asthma in clinical practice in France. Clinical Therapeutics 2008; 30: 1058-1068.
15. http://www.cnil.fr. [Accessed 18 February 2009].
16. Lenormand F. Le système d'information de l'assurance maladie, le sniir-am et les échantillons de bénéficiaires. Courrier des statistiques 2005: 33-51. French.
17. Allenbach D, Montagnier B, Souche A, et al. The population treated with anti-tuberculosis agents in 2003: data from the general scheme of the French healthcare fund. Rev Med Ass Maladie 2004; 35: 223-232. French.
18. Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Dermatol 2006; 16: 669-673.
19. Auleley GR, Deligne J, Hantson C, et al. Selective cyclooxygenase-2 inhibitors. A population-based analysis of use in France over a three-year period and comparison with randomised clinical trials. Presse Med 2005; 34: 703-710. French.
20. Auleley GR, Dematons MN, Berchery P, et al. Type 2 diabetes mellitus among beneficiaries of the french national health insurance for self-employed workers (AMPI): comparison of the management of craftsmen or tradesmen with professionals patients. Diabetes Metab 2002; 28: 491-498.
21. Bensouda-Grimaldi L, Sarraf N, Doisy F, et al. Prescription of drugs contraindicated in children: a national community survey. Eur J Clin Pharmacol 2007; 63: 99-101.
22. Berchery D, Roussel H, Bourrel R, et al. Outpatient use of heparin: data from the Midi-Pyrenes Health Fund. Therapie 2003; 58: 431-437. French.
23. Besancon JF, Lagarce L, Diquet B, et al. Study of the use of a spironolactone and angiotensin-converting enzyme inhibitor combination: a population-based analysis. Pharmacoepidemiol Drug Saf 2008; 17: 172-179.
24. Beyens MN, Guy C, Ratrema M, et al. Prescription of drugs to pregnant women in France: the HIMAGE study. Therapie 2003; 58: 505-511. French.
25. Bigouroux V, Roussel H, Souche A, et al. The use of clomiphene citrate in ambulatory medicine practice in the Midi-Pyrenees area: compliance to national guidelines applicable to infertility diagnosis and to prescription and monitoring rules applicable to clomiphene citrate treatments. Gynecol Obstet Fertil 2004; 32: 954-960. French.
26. Bocquet A, Chalumeau M, Bollotte D, et al. Comparison of prescriptions by pediatricians and general practitioners: a population-based study in Franche-Comte from the database of Regional Health Insurance Fund. Arch Pediatr 2005; 12: 1688-1696. French.
27. Bocquier A, Bezzou K, Nauleau S, et al. Dispensing of anxiolytics and hypnotics in southeastern France: demographic factors and determinants of geographic variations. Fundam Clin Pharmacol 2008; 22: 323-333.
28. Bocquier A, Nauleau S, Verger P. Relevance of the health insurance databases to study health spatial disparities: example of anxiolytics and hypnotics in southeastern France in 2005. Prat Organ Soins 2009; 40: 91-98. French.
29. Brefel-Courbon C, Grolleau S, Thalamas C, et al. Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population. Pain 2009; 141: 14-18.
30. Briffault X, Sapinho D, Villamaux M, et al. Factors associated with use of psychotherapy. Soc Psychiatry Psychiatr Epidemiol 2008; 43: 165-171.
31. Chastagner M, Gault M, Aboyans V, et al. A long-term follow-up quality evaluation of patients taking oral anticoagulant therapy. Arch Mal Coeur Vaiss 2005; 98: 199-204. French.
32. Chevalier C, Giral P, Chinaud F, et al. Application of medical guidelines for the prescription of statins. Rev Epidemiol Sante Publique 2002; 50: 463-473. DOI MDOI-RESP-10-2002-50-5-0398-7620-101019.-ART7 [pii] French.
33. Chevalier C, Giral P, Oger C, et al. Changes in biological test practices after publication of national guidelines for lipid management among patients under statin treatment. Rev Epidemiol Sante Publique 2005; 53: 393-397. French.
34. Christophe B, Gillet A, MejecaseM. Allergy to ragweed in the Rhone-Alpes and consumption of anti-allergics. Eur Ann Allergy Clin Immunol 2004; 36: 333-336. French.
35. Claroux-Bellocq D, De Bailliencourt S, Saint-Jean F, et al. Substitute drug treatment for opiate addiction in metropolitan France in 2000: data from the general healthcare fund. Rev Med Ass Maladie 2003; 34: 93-102. French.
36. Damagnez M, Magnouat A, Niezborala J, et al. Drugs contraindicated in children: a study of drug prescriptions in ambulatory medicine in the south of France (Aude Department). Therapie 2005; 60: 507-513. French.
37. de la Seigliere A, Ketterer JP, Delforge B, et al. Health care in non-insulin dependent diabetics in lower Normandy. Diabetes Metab 2000; 26 (Suppl 6): 86-94. French.
38. de Wazieres B, Carol C, Vernaz J, et al. Study of drug prescribing in patients older than 65 in Languedoc-Roussillon. Rev Med Interne 2002; 23: 745-750. French.
39. Depont F, Fourrier A, Merliere Y, et al. The CADEUS study: methods and logistics. Pharmacoepidemiol Drug Saf 2007; 16: 571-580. DOI:10.1002/pds.1348 [doi]. eng
40. Depont F, Fourrier A, Merliere Y, et al. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Pharmacoepidemiol Drug Saf 2007; 16: 891-900.
41. Deprez P-H, Chinaud F, Clech S, et al. Patients treated with antiasthmatic medications in metropolitan France: the National Health Fund's 2000 Data. Rev Med Ass Maladie 2004; 35: 3-11. French.
42. Desboeuf K, Grau M, Riche F, et al. Prevalence and costs of parkinsonian syndromes associated with orthostatic hypotension. Therapie 2006; 61: 93-99.
43. Dif C, Winter G. High-dose buprenorphine: three-year follow-up of 285 patients. Rev Med Ass Maladie 2005; 36: 143-151. French.
44. Fagot-Campagna A, Romon I, Poutignat N, et al. Non-insulin treated diabetes: relationship between disease management and quality of care. The Entred study, 2001. Rev Prat 2007; 57: 2209-2216. French.
45. Fender P, Guilhot J, Tilly B, et al. Treatment of severe arterial hypertension: cost of drug prescriptions in accordance with ANAES guidelines. Therapie 2001; 56: 111-118. French.
46. Feroni I, Aubisson S, Bouhnik AD, et al. Collaboration between general practitioners and pharmacists in the management of patients on high-dosage buprenorphine treatment. Prescribers' practices. Presse Med 2005; 34: 1213-1219. French.
47. Feroni I, Paraponaris A, Aubisson S, et al. Prescription of high dose buprenorphine by general practitioners. Rev Epidemiol Sante Publique 2004; 52: 511-522. French.
48. Fourgon R, Vicrey C, Blanchon B, et al. The editorial quality of hospital drug prescriptions in the Ile de France area. A study by the Health Insurance. Presse Med 2005; 34: 203-207. French.
49. Fourrier-Reglat A, de Bailliencourt S, Molimard M, et al. Celecoxib prescription: data from the "Securite Sociale" database of the Aquitaine Region, South-Western, France. Therapie 2005; 60: 25-29. French.
50. Fourrier-Reglat A, Droz-Perroteau C, Benichou J, et al. Impact of prescriber nonresponse on patient representativeness. Epidemiology 2008; 19: 186-190.
51. Frauger E, Pradel V, Natali F, et al. Misuse of clonazepam (Rivotril): recent trends. Therapie 2006; 61: 49-55. French.
52. Frauger E, Thirion X, Chanut C, et al. Misuse of trihexyphenidyl (Artane, Parkinane): recent trends. Therapie 2003; 58: 541-547. French.
53. Fuhrman C, Sarter H, Thibaudon M, et al. Short-term effect of pollen exposure on antiallergic drug consumption. Annals of Allergy, Asthma and Immunology 2007; 99: 225-231.
54. Gayet-Ageron A, Amamra N, Ringa V, et al. Estimated numbers of postmenopausal women treated by hormone therapy in France. Maturitas 2005; 52: 296-305.
55. Gerardin-Marais M, Victorri-Vigneau C, Allain-Veyrac G, et al. Diuretic drug therapy monitoring in the elderly: a cohort study. Eur J Clin Pharmacol 2008; 64: 433-437.
56. Guedon-Moreau L, Ducrocq D, Duc MF, et al. Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 2003; 59: 689-695. DOI:10.1007/ s00228-003-0684- 1[doi]. eng
57. Guedon-Moreau L, Ducrocq D, Duc MF, et al. Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 2004; 59: 899-904.
58. Hourcade S, Burbaud F, Loustaud-Ratti V. Care to patients with hepatitis C who were treated with viral agents in the Limousin region. Rev Med Ass Maladie 2005; 36: 217-226. French.
59. Huot L, Couris CM, Tainturier V, et al. Trends in HRT and antiosteoporosis medication prescribing in a European population after the WHI study. Osteoporos Int 2008; 19: 1047-1054.
60. Hurault C, Lacroix I, Bourrel R, et al. Writing and dispensing of NSAID prescriptions in late pregnancy: impact of health authorities' advice. Presse Med 2008; 37: 767-774. In French.
61. Jeantet M, Gosselin S, Lefrand E, et al. Medical management of patients with stable coronary artery disease in France in 2004. Data from the Mutualite Sociale Agricole. Presse Med 2006; 35: 1123-1130. French.
62. Jounieaux V, Guillaume C, Malka M, et al. Medico-economic evaluation of a care management program for asthmatic patients. Sante Publique 2003; 15: 449-464. French.
63. Juillard-Condat B, Constantin A, Cambon-Thomsen A, et al. Cost of rheumatoid arthritis in france: comparison leflunomide/etanercept. Therapie 2007; 62: 137-142. French.
64. Juillard-Condat B, Constantin A, Cambon-Thomsen A, et al. Impact of etanercept on the costs of rheumatoid arthritis (RA): results from a French observational study. Joint Bone Spine 2008; 75: 25-28.
65. Karsenty D, Bourdel H, Cherrier C, et al. The patient population treated with anti-epileptic drugs in metropolitan France in 2000: data from the general scheme of the French national health insurance fund. Rev Med Ass Maladie 2005; 36: 123-132. French.
66. Kazaz E, Grisouard R, Zanni J, et al. Multiple Sclerosis treated with β-interferon: prevalence and cost for the public health fund in 2000. Rev Med Ass Maladie 2003; 34: 147-156. French.
67. Knellwolf AL, Deligne J, Chiarotti F, et al. Prevalence and patterns of methylphenidate use in French children and adolescents. Eur J Clin Pharmacol 2008; 64: 311-317.
68. Kuhn F, Pédaillès S, Pull M, et al. Consistency of initiation of treatment with specific serotonin reuptake inhibitors with their marketing authorisations. Rev Med Ass Maladie 2006; 37: 1-7. French.
69. Kusnik-Joinville O, Tuppin P, Lamy C, et al. Diagnosed and treated Alzheimer disease and other dementia among 60 years and more in France during 2007: population and healthcare use. Prat Organ Soins 2009; 40: 81-90. French.
70. Kusnik-Joinville O, Weill A, Salanave B, et al. Prevalence and treatment of diabetes in France: trends between 2000 and 2005. Diabetes Metab 2008; 34: 266-272.
71. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, et al. Prescription of drugs during pregnancy in France. Lancet 2000; 356: 1735-1736.
72. Lapeyre-Mestre M, Llau ME, Gony M, et al. Opiate maintenance with buprenorphine in ambulatory care: a 24-week follow-up study of new users. Drug Alcohol Depend 2003; 72: 297-303.
73. Laurent O, Pedrono G, Filleul L, et al. Influence of socioeconomic deprivation on the relation between air pollution and beta-agonist sales for asthma. Chest 2009; 135: 717-723.
74. Lecadet J, Vidal P, Baris B, et al. Psychotropic medications: prescriptions and use in metropolitan France.II. National data for 2000. Rev Med Ass Maladie 2003; 34: 223-248. French.
75. Lecadet J, Vidal P, Vialaret K, et al. Antidepressant medications: change in consumption between 2000 and 2003 in the Auvergne region. Rev Med Ass Maladie 2006; 37: 9-14. French.
76. Lecomte P, Romon I, Fosse S, et al. Self-monitoring of blood glucose in people with type 1 and type 2 diabetes living in France: the Entred study 2001. Diabetes Metab 2008; 34: 219-226.
77. Levy L, Martin-Guehl C, Lechevallier-Michel N, et al. Use of psychotropic drugs in 0 to 5 years old children in Aquitaine (France): prevalence and associated factors. Pharmacoepidemiol Drug Saf 2006; 15: 504-509.
78. Lévy P, Fanello S, Pivette J, et al. Nonsteroidal anti-inflammatory drugs and potential iatrogenic risks: an analysis using the French national health fund's database. Rev Med Ass Maladie 2005; 36: 153-161. French.
79. Levy-Neumand O, Gillet A, Christophe B, et al. Migraine: long-term treatment and medication abuse. Prat Organ Soins 2006; 37: 325-332. French.
80. Lugardon S, Roussel H, Bourrel R, et al. Patterns of non steroidal anti-inflammatory drug use in ambulatory care. Therapie 2006; 61: 109-114. French.
81. Lugardon S, Roussel H, Sciortino V, et al. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database. Eur J Clin Pharmacol 2007; 63: 801-807.
82. Magnier V, Flipon E, Godefroy O, et al. Acetylcholinesterase inhibitor treatment for Alzheimer's disease: the experience in Picardy. Rev Neurol (Paris) 2005; 161: 211-213. French.
83. Mahr A, Belarbi L, Wechsler B, et al. Population-based prevalence study of Behcet's disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 2008; 58: 3951-3959.
84. Mahr A, Guillevin L, Poissonnet M, et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 51: 92-99.
85. Mancini J, Thirion X, Masut A, et al. Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002. Pharmacoepidemiol Drug Saf 2006; 15: 494-503.
86. Marant C, Romon I, Fosse S, et al. French medical practice in type 2 diabetes: the need for better control of cardiovascular risk factors. Diabetes Metab 2008; 34: 38-45.
87. Marquaille V, Rempp R, Dechamp C, et al. Celecoxib: a study of the disorders motivating its outpatient prescription in the light of its official therapeutic indications. Rev Med Ass Maladie 2003; 34: 167-173. French.
88. Martin K, Begaud B, Latry P, et al. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 2004; 57: 86-92.
89. Martin K, Begaud B, Verdoux H, et al. Patterns of risperidone prescription: a utilization study in south-west France. Acta Psychiatr Scand 2004; 109: 202-206. DOI 238 [pii]. eng
90. Martin-Latry K, Goumy MP, Latry P, et al. Psychotropic drugs use and risk of heat-related hospitalisation. Eur Psychiatry 2007; 22: 335-338.
91. Micallef J, Pradel V, Thirion X, et al. Use of the health insurance database by the centres for evaluation and information on pharmacodependance: examples, interests and future prospects. Therapie 2004; 59: 581-588. French.
92. Mikaeloff Y, Moride Y, Khoshnood B, et al. Infant and toddler disease score was useful for risk of hospitalization based on data from administrative claims. J Clin Epidemiol 2007; 60: 680-685.
93. Modica M, Vanhems P, Tebib J. Comparison of conventional NSAIDs and cyclooxygenase-2 inhibitors in outpatients. Joint Bone Spine 2005; 72: 397-402.
94. Moore N, Diris H, Martin K, et al. NSAID use profiles derived from reimbursement data in France. Therapie 2004; 59: 541-546. eng.
95. Noize N, Bazin F, Dufouil C, et al. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study. Pharmacoepidemiol Drug Saf 2009; 18: 310-319.
96. Pariente A, Helmer C, Merliere Y, et al. Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiol Drug Saf 2008; 17: 655-660.
97. Parjoie R, Tassin J, Parotte M, et al. Analysis of the prescription and delivery of seven generic drug formulations in Champagne-Ardenne and Lorraine. Rev Med Ass Maladie 2004; 35: 109-118. French.
98. Perearnau P, Hessemann H, Weill G. The Use of Vasoconstrictors in Benign Upper Respiratory Disorders in Children: a Common Practice With Under-estimated Risks. Rev Med Ass Maladie 2003; 34: 33-40. French.
99. Perearnau P, Vuillemet F, Schick J, et al. Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable. Rev Neurol (Paris) 2006; 162: 347-357. French.
100. Pitard A, Zeghnoun A, Courseaux A, et al. Short-term associations between air pollution and respiratory drug sales. Environ Res 2004; 95: 43-52.
101. Pradel V, Frauger E, Thirion X, et al. Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiol Drug Saf 2009; 18: 36-43.
102. Pradel V, Thirion X, Ronfle E, et al. Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database. Pharmacoepidemiol Drug Saf 2004; 13: 473-481.
103. Ricordeau P, Weill A, Vallier N, et al. The cost of diabetes in metropolitan France. Diabetes Metab 2000; 26 (Suppl 6): 25-38. French.
104. Ricordeau P, Weill A, Vallier N, et al. The prevalence and cost of diabetes in metropolitan France: what trends between 1998 and 2000? Diabetes Metab 2003; 29: 497-504.
105. Roossens JP, Poulalion L, Beigbeder I, et al. Identification of factors hindering better management of patients with type 2 diabetes. Diabetes Metab 2000; 26 (Suppl 6): 77-85. French.
106. Rossignol M, Abouelfath A, Lassalle R, et al. The CADEUS study: burden of nonsteroidal anti-inflammatory drug (NSAID) utilization for musculoskeletal disorders in blue collar workers. Br J Clin Pharmacol 2009; 67: 118-124.
107. Saba G,Weill A, Païta M, et al. Dyslipidemia: how well were practice guidelines followed before initiating treatment with lipid-lowering agents in 2002 in France? Rev Med Ass Maladie 2003; 34: 221-231. French.
108. Sailler L, Pereira C, Bagheri A, et al. Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Ann Rheum Dis 2008; 67: 614-619.
109. Schick J, Willem P, Weill G. Prescriptions of Psychotropic Medications in Children and Adolescents in the Alsace Region in 2002. Rev Med Ass Maladie 2004; 35: 13-18. French.
110. Silvéra L, Flori Y, Slota L, et al. Cost to the general scheme of the health insurance fund and distinctive features of the outpatient population treated with antiretroviral therapy in 2000 in metropolitan France. Rev Med Ass Maladie 2004; 35: 233-242. French.
111. Thirion X, Lapierre V, Micallef J, et al. Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend 2002; 65: 197-204.
112. Tilly B, Salanave B, Ricordeau P, et al. Severe high blood pressure in France: Treatment and blood pressure control in 1999 and 2003. Rev Med Ass Maladie 2004; 35: 167-180. French.
113. Tuppin P, Neumann A, Danchin N, et al. Combined secondary prevention after hospitalization for myocardial infarction in France: analysis from a large administrative database. Archives of Cardiovascular Diseases 2009; 102: 279-292.
114. Vauzelle-Kervroedan F, Javoy F, Forhan A, et al. Pharmacoepidemiology of diabetes: assessment of good use of oral antidiabetic drugs. Diabetes Metab 2000; 26 (Suppl 6): 63-68. French.
115. Verger P, Clavaud H, Bidaud S, et al. Analgesic and anti-inflammatory drug prescriptions and number of radiograms predict antidepressant treatment: study of reimbursement data from the Provence health insurance fund. Presse Med 2007; 36: 50-56. French.
116. Vicrey C, Bayet JF, Extra JM, et al. Prescription of diphosphonates in ambulatory oncology. A study of the health insurance medical services. Presse Med 1996; 25: 1101-1104. French.
117. Victorri-Vigneau C, Basset G, Bourin M, et al. Impacts of the new flunitrazepam regulations on the consumption of hypnotics. Therapie 2003; 58: 425-430. French.
118. Victorri-Vigneau C, Basset G, Jolliet P. How a novel programme for increasing awareness of health professionals resulted in a 14% decrease in patients using excessive doses of psychotropic drugs in western France. Eur J Clin Pharmacol 2006; 62: 311-316.
119. Victorri-Vigneau C, Marais M, Veyrac G, et al. Reactivity and communication of Health Authorities toward health professionals: a public health priority. Therapie 2007; 62: 513-517. French.
120. Vidal JS, Lacombe JM, Dartigues JF, et al. Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiology 2008; 31: 193-200.
121. Vidal JS, Lacombe JM, Dartigues JF, et al. Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients. Alzheimer Dis Assoc Disord 2008; 22: 125-130. DOI:10.1097/WAD.0b013e31815a9e10 [doi] 00002093.-200804000-00006[pii]. eng
122. Weill A, Ricordeau P, Vallier N, et al. Analysis of health insurance benefits: material and methods. Diabetes Metab 2000; 26 (Suppl 6): 49-54. French.
123. Weill A, Ricordeau P, Vallier N, et al. Modalities of follow-up on non-insulin treated diabetics treated in metropolitan France in 1998. Diabetes Metab 2000; 26 (Suppl 6): 39-48. French.
124. Zeghnoun A, Ravault C, Fabres B, et al. Short-term effects of airborne pollen on the risk of allergic rhinoconjunctivitis. Arch Environ Occup Health 2005; 60: 170-176.
125. Situation de l'automédication en France et perspectives d'évolution. http://www.sante.gouv.fr/htm/actu/automedication/rapport.pdf (Accessed 20 July 2009).